Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Nuclear Medicine Communications|December 10, 2021
Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisationAtul Gosavi, Ameya D Puranik, Sneha Shah, et al.
Nuclear Medicine Communications|December 11, 2020
Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolizationAmeya D Puranik, Venkatesh Rangarajan, Atul Gosavi, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 13, 2021
Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomasAmeya D Puranik, Venkatesh Rangarajan, Indraja D Dev, et al.
Indian Journal of Cancer|March 1, 2024
Tata Memorial Centre Evidence Based Use of Nuclear medicine diagnostic and treatment modalities in cancerAmeya D Puranik, Sayak Choudhury, Suchismita Ghosh, et al.
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|July 11, 2024
Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and ToxicityAmeya D Puranik, Venkatesh Rangarajan, Nitin Sudhakar Shetty, et al.
Indian Journal of Surgical Oncology|April 25, 2022
An Audit of Systemic Therapy in Medullary Carcinoma ThyroidAditya Pavan Kumar Kanteti, George Abraham, Vijay M Patil, et al.
Neurology India|May 1, 2024
PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology CenterAmeya D Puranik, Indraja D Dev, Venkatesh Rangarajan, et al.
BMC Cancer|October 29, 2025
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Ameya D Puranik, Indraja D Dev, Sushil Yadav, et al.
Neuroradiology|November 11, 2024
FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled studyAmeya D Puranik, Indraja D Dev, Venkatesh Rangarajan, et al.
Pageof 9